> Details

Rebuzzi, Sara Elena; Brunelli, Matteo; Galuppini, Francesca; Vellone, Valerio Gaetano; Signori, Alessio; Catalano, Fabio; Damassi, Alessandra; Gaggero, Gabriele; Rescigno, Pasquale; Maruzzo, Marco; Merler, Sara; Vignani, Francesca; Cavo, Alessia; Basso, Umberto; Milella, Michele; Panepinto, Olimpia; Mencoboni, Manlio; Sbaraglia, Marta; Dei Tos, Angelo Paolo; Murianni, Veronica; Cremante, Malvina; Llaja Obispo, Miguel Angel; Maffezzoli, Michele; Banna, Giuseppe Luigi; [...]

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
  • Contributor: Rebuzzi, Sara Elena; Brunelli, Matteo; Galuppini, Francesca; Vellone, Valerio Gaetano; Signori, Alessio; Catalano, Fabio; Damassi, Alessandra; Gaggero, Gabriele; Rescigno, Pasquale; Maruzzo, Marco; Merler, Sara; Vignani, Francesca; Cavo, Alessia; Basso, Umberto; Milella, Michele; Panepinto, Olimpia; Mencoboni, Manlio; Sbaraglia, Marta; Dei Tos, Angelo Paolo; Murianni, Veronica; Cremante, Malvina; Llaja Obispo, Miguel Angel; Maffezzoli, Michele; Banna, Giuseppe Luigi; [...]
  • imprint: MDPI AG, 2023
  • Published in: Cancers
  • Language: English
  • DOI: 10.3390/cancers15082394
  • ISSN: 2072-6694
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:p>Background: Prognostic and predictive factors for patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy are highly warranted, and the immune tumor microenvironment (I-TME) is under investigation. Methods: The Meet-URO 18 was a multicentric retrospective study assessing the I-TME in mRCC patients treated with ≥2nd-line nivolumab, dichotomized into responders and non-responders according to progression-free survival (≥12 months and ≤3 months, respectively). The primary objective was to identify differential immunohistochemical (IHC) patterns between the two groups. Lymphocyte infiltration and the expressions of different proteins on tumor cells (CD56, CD15, CD68, and ph-mTOR) were analyzed. The expression of PD-L1 was also assessed. Results: A total of 116 tumor tissue samples from 84 patients (59% were primary tumors and 41% were metastases) were evaluated. Samples from responders (N = 55) were significantly associated with lower expression of CD4+ T lymphocytes and higher levels of ph-mTOR and CD56+ compared with samples from non-responders (N = 61). Responders also showed a higher CD3+ expression (p = 0.059) and CD8+/CD4+ ratio (p = 0.084). Non-responders were significantly associated with a higher percentage of clear cell histology and grading. Conclusions: Differential IHC patterns between the tumors in patients who were responders and non-responders to nivolumab were identified. Further investigation with genomic analyses is planned.</jats:p>
  • Access State: Open Access